Neurocrine Biosciences (NBIX) Tops Q4 EPS by 12c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $161.62 --0%
EPS Growth %: -5.5%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -5.5%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.69, $0.12 better than the analyst estimate of $1.57. Revenue for the quarter came in at $627.7 million versus the consensus estimate of $630.01 million.
GUIDANCE:
Neurocrine Biosciences sees FY2025 revenue of $2.5-2.6 billion, versus the consensus of $2.35 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- RBC Capital Starts Molina Healthcare (MOH) at Sector Perform
- VIAVI launches Ultra Ethernet Transport validation tool for AI networks
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
